Chapter 5 Virulence in Cryptococcus Species

Advances in Applied Microbiology

Volumn 67, Issue C, 2009, Pages 131-190

  Ma, Hansong ^a   May, Robin C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRULENCE FACTOR;

ANIMAL; CLASSIFICATION; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DOG; GENE EXPRESSION REGULATION; GENETICS; GUINEA PIG; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; RAT; REVIEW; SIGNAL TRANSDUCTION; VIRULENCE;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DOGS; GENE EXPRESSION REGULATION, BACTERIAL; GUINEA PIGS; HOST-PATHOGEN INTERACTIONS; HUMANS; RATS; SIGNAL TRANSDUCTION; VIRULENCE; VIRULENCE FACTORS;

EID: 60549098253     PISSN: 00652164     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2164(08)01005-8     Document Type: Review

References (366)

1. Akhter S., McDade H.C., Gorlach J.M., Heinrich G., Cox G.M., and Perfect J.R. Role of alternative oxidase gene in pathogenesis of Cryptococcus neoformans. Infect. Immun. 71 (2003) 5794-5802
2. Aksenov S.I., Babyeva I.P., and Golubev V.I. On the mechanism of adaptation of micro-organisms to conditions of extreme low humidity. Life Sci. Space Res. 11 (1973) 55-61
3. Alspaugh J.A., Cavallo L.M., Perfect J.R., and Heitman J. RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Mol. Microbiol. 36 (2000) 352-365
4. Alspaugh J.A., Perfect J.R., and Heitman J. Cryptococcus neoformans mating and virulence are regulated by the G-protein alpha subunit GPA1 and cAMP. Genes. Dev. 11 (1997) 3206-3217
5. Alspaugh J.A., Perfect J.R., and Heitman J. Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans. Fungal Genet. Biol. 25 (1998) 1-14
6. Alspaugh J.A., Pukkila-Worley R., Harashima T., Cavallo L.M., Funnell D., Cox G.M., Perfect J.R., Kronstad J.W., and Heitman J. Adenylyl cyclase functions downstream of the Galpha protein Gpa1 and controls mating and pathogenicity of Cryptococcus neoformans. Eukaryotic Cell 1 (2002) 75-84
7. Alvarez M., and Casadevall A. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr. Biol. 16 (2006) 2161-2165
8. Alvarez M., and Casadevall A. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol. 8 (2007) 16
9. Alvarez M., Saylor C., and Casadevall A. Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation. Cell. Microbiol. (2008) (Epub ahead of print)
10. Antinori S. Cryptococcosis: We should do better!. Clin. Infect. Dis. 43 (2006) 948-949
11. Apidianakis Y., Rahme L.G., Heitman J., Ausubel F.M., Calderwood S.B., and Mylonakis E. Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response. Eukaryotic Cell 3 (2004) 413-419
12. Baddley J.W., Perfect J.R., Oster R.A., Larsen R.A., Pankey G.A., Henderson H., Haas D.W., Kauffman C.A., Patel R., Zaas A.K., and Pappas P.G. Pulmonary cryptococcosis in patients without HIV infection: Factors associated with disseminated disease. Eur. J. Clin. Microbiol. Infect. Dis. (2008) (Epub ahead of print)
13. Bahn Y.S., Kojima K., Cox G.M., and Heitman J. Specialization of the HOG pathway and its impact on differentiation and virulence of Cryptococcus neoformans. Mol. Biol. Cell 16 (2005) 2285-2300
14. Bahn Y.S., Kojima K., Cox G.M., and Heitman J. A unique fungal two-component system regulates stress responses, drug sensitivity, sexual development, and virulence of Cryptococcus neoformans. Mol. Biol. Cell 17 (2006) 3122-3135
15. Baker R.D. The primary pulmonary lymph node complex of cryptococcosis. Am. J. Clin. Pathol. 65 (1976) 83-92
16. Bar-Peled M., Griffith C.L., and Doering T.L. Functional cloning and characterization of a UDP- glucuronic acid decarboxylase: The pathogenic fungus Cryptococcus neoformans elucidates UDP-xylose synthesis. Proc. Natl. Acad. Sci. USA 98 (2001) 12003-12008
17. Barchiesi F., Cogliati M., Esposto M.C., Spreghini E., Schimizzi A.M., Wickes B.L., Scalise G., and Viviani M.A. Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis. J. Infect. 51 (2005) 10-16
18. Bartlett K.H., Kidd S.E., and Kronstad J.W. The Emergence of Cryptococcus gattii in British Columbia and the Pacific Northwest. Curr. Fungal Infect. Rep. 1 (2007) 108-115
19. Baum G.L., and Artis D. Growth inhibition of Cryptococcus neoformans by cell free human serum. Am. J. Med. Sci. 241 (1961) 613-616
20. Baum G.L., and Artis D. Characterization of the Growth Inhibition Factor for Cryptococcus neoformans (Gifc) in Human Serum. Am. J. Med. Sci. 246 (1963) 53-57
21. Bennett J.E., Dismukes W.E., Duma R.J., Medoff G., Sande M.A., Gallis H., Leonard J., Fields B.T., Bradshaw M., Haywood H., McGee Z.A., Cate T.R., et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301 (1979) 126-131
22. Blackstock R., and Murphy J.W. Role of interleukin-4 in resistance to Cryptococcus neoformans infection. Am. J. Respir. Cell Mol. Biol. 30 (2004) 109-117
23. Bicanic T., and Harrison T.S. Cryptococcal meningitis. Br. Med. Bull. 72 (2004) 99-118
24. Bii C.C., Makimura K., Abe S., Taguchi H., Mugasia O.M., Revathi G., Wamae N.C., and Kamiya S. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 50 (2007) 25-30
25. Boekhout T., Theelen B., Diaz M., Fell J.W., Hop W.C., Abeln E.C., Dromer F., and Meyer W. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 147 (2001) 891-907
26. Boekhout T., van Belkum A., Leenders A.C., Verbrugh H.A., Mukamurangwa P., Swinne D., and Scheffers W.A. Molecular typing of Cryptococcus neoformans: Taxonomic and epidemiological aspects. Int. J. Syst. Bacteriol. 47 (1997) 432-442
27. Bolanos B., and Mitchell T.G. Phagocytosis of Cryptococcus neoformans by rat alveolar macrophages. J. Med. Vet. Mycol. 27 (1989) 203-217
28. Bovers M., Hagen F., Kuramae E.E., and Boekhout T. Six monophyletic lineages identified within Cryptococcus neoformans and Cryptococcus gattii by multi-locus sequence typing. Fungal Genet. Biol. 45 (2008) 400-421
29. Bovers M., Hagen F., Kuramae E.E., Diaz M.R., Spanjaard L., Dromer F., Hoogveld H.L., and Boekhout T. Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res. 6 (2006) 599-607
30. Bozzette S.A., Larsen R.A., Chiu J., Leal M.A., Jacobsen J., Rothman P., Robinson P., Gilbert G., McCutchan J.A., and Tilles J. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N. Engl. J. Med. 324 (1991) 580-584
31. Brajtburg J., Powderly W.G., Kobayashi G.S., and Medoff G. Amphotericin B: Current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34 (1990) 183-188
32. Brandt M.E., Hutwagner L.C., Kuykendall R.J., and Pinner R.W. Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of Cryptococcus neoformans. The Cryplococcal Disease Active Surveillance Group. J. Clin. Microbiol. 33 (1995) 1890-1895
33. Brodie S.J., Sasseville V.G., Reimann K.A., Simon M.A., Sehgal P.K., and Ringler D.J. Macrophage function in simian AIDS. Killing defects in vivo are independent of macrophage infection, associated with alterations in Th phenotype, and reversible with IFN-gamma. J. Immunol. 153 (1994) 5790-5801
34. Brouwer A.E., Rajanuwong A., Chierakul W., Griffin G.E., Larsen R.A., White N.J., and Harrison T.S. Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial. Lancet 363 (2004) 1764-1767
35. Brummer E., and Stevens D.A. Effect of macrophage colony-stimulating factor (M-CSF) on macrophage morphology, phagocytosis, and intracellular multiplication of Histoplasma capsulatum. Int. J. Immunopharmacol. 16 (1994) 171-176
36. Bunting L.A., Neilson J.B., and Bulmer G.S. Cryptococcus neoformans: Gastronomic delight of a soil ameba. Sabouraudia 17 (1979) 225-232
37. Buschke A. Über eine durch coccidien hervergerufene krankheit des menschen. Dtsch. Med. Wochenschr. 21 (1895) 14
38. Busse O. Über parasitare Zelleinschlüsse und ihre Züchtung. Zentralbl. Bakteriol. 16 (1894) 175-180
39. Campbell L.T., Fraser J.A., Nichols C.B., Dietrich F.S., Carter D., and Heitman J. Clinical and environmental isolates of Cryptococcus gattii from Australia that retain sexual fecundity. Eukaryotic Cell 4 (2005) 1410-1419
40. Carroll S.F., Guillot L., and Qureshi S.T. Mammalian model hosts of cryptococcal infection. Comp. Med. 57 (2007) 9-17
41. Casadevall A., Cleare W., Feldmesser M., Glatman-Freedman A., Goldman D.L., Kozel T.R., Lendvai N., Mukherjee J., Pirofski L.A., Rivera J., Rosas A.L., Scharff M.D., et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42 (1998) 1437-1446
42. Casadevall A., and Perfect J. Cryptococcus neoformans (1998), ASM Press
43. Casadevall A., Rosas A.L., and Nosanchuk J.D. Melanin and virulence in Cryptococcus neoformans. Curr. Opin. Microbiol. 3 (2000) 354-358
44. Casadevall A., Steenbergen J.N., and Nosanchuk J.D. 'Ready made' virulence and 'dual use' virulence factors in pathogenic environmental fungi-the Cryptococcus neoformans paradigm. Curr. Opin. Microbiol. 6 (2003) 332-337
45. Chang Y.C., Cherniak R., Kozel T.R., Granger D.L., Morris L.C., Weinhold L.C., and Kwon-Chung K.J. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene. Infect. Immun. 65 (1997) 1584-1592
46. Chang Y.C., and Kwon-Chung K.J. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol. 14 (1994) 4912-4919
47. Chang Y.C., and Kwon-Chung K.J. Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect. Immun. 66 (1998) 2230-2236
48. Chang Y.C., and Kwon-Chung K.J. Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. J. Bacteriol. 181 (1999) 5636-5643
49. Chang Y.C., Penoyer L.A., and Kwon-Chung K.J. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect. Immun. 64 (1996) 1977-1983
50. Chang Y.C., Stins M.F., McCaffery M.J., Miller G.F., Pare D.R., Dam T., Paul-Satyaseela M., Kim K.S., and Kwon-Chung K.J. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect. Immun. 72 (2004) 4985-4995
51. Chang Y.C., Wickes B.L., and Kwon-Chung K.J. Further analysis of the CAP59 locus of Cryptococcus neoformans: Structure defined by forced expression and description of a new ribosomal protein-encoding gene. Gene 167 (1995) 179-183
52. Chang Y.C., Wickes B.L., Miller G.F., Penoyer L.A., and Kwon-Chung K.J. Cryptococcus neoformans STE12alpha regulates virulence but is not essential for mating. J. Exp. Med. 191 (2000) 871-882
53. Chaturvedi S., Ren P., Narasipura S.D., and Chaturvedi V. Selection of optimal host strain for molecular pathogenesis studies on Cryptococcus gattii. Mycopathologia 160 (2005) 207-215
54. Chaturvedi V., Wong B., and Newman S.L. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J. Immunol. 156 (1996) 3836-3840
55. Chen L.C., Blank E.S., and Casadevall A. Extracellular proteinase activity of Cryptococcus neoformans. Clin. Diagn. Lab. Immunol. 3 (1996) 570-574
56. Chen G.H., Curtis J.L., Mody C.H., Christensen P.J., Armstrong L.R., and Toews G.B. Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J. Immunol. 152 (1994) 724-734
57. Chen G.H., McNamara D.A., Hernandez Y., Huffnagle G.B., Toews G.B., and Olszewski M.A. Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infect. Immun. 76 (2008) 2379-2391
58. Chen S.C.A., Muller M., Jin Zhong Z., Wright L.C., and Sorrell T.C. Phospholipase Activity in Cryptococcus neoformans: A new virulence factor?. J. Infect. Dis. 175 (1997) 414-420
59. Chen J., Varma A., Diaz M.R., Litvintseva A.P., Wollenberg K.K., and Kwon-Chung K.J. Cryptococcus neoformans Strains and Infection in Apparently Immunocompetent Patients, China. Emerg. Infect. Dis. 14 (2008) 755-762
60. Chen S., Sorrell T., Nimmo G., Speed B., Currie B., Ellis D., Marriott D., Pfeiffer T., Parr D., and Byth K. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin. Infect. Dis. 31 (2000) 499-508
61. Chen S.H., Stins M.F., Huang S.H., Chen Y.H., Kwon-Chung K.J., Chang Y., Kim K.S., Suzuki K., and Jong A.Y. Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J. Med. Microbiol. 52 (2003) 961-970
62. Cherniak R., Morris L.C., Belay T., Spitzer E.D., and Casadevall A. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect. Immun. 63 (1995) 1899-1905
63. Chretien F., Lortholary O., Kansau I., Neuville S., Gray F., and Dromer F. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J. Infect. Dis. 186 (2002) 522-530
64. Clancy C.J., Nguyen M.H., Alandoerffer R., Cheng S., Iczkowski K., Richardson M., and Graybill J.R. Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. Microbiology 152 (2006) 2247-2255
65. Clemons K.V., Azzi R., and Stevens D.A. Experimental systemic cryptococcosis in SCID mice. J. Med. Vet. Mycol. 34 (1996) 331-335
66. Clemons K.V., Brummer E., and Stevens D.A. Cytokine treatment of central nervous system infection: Efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob. Agents Chemother. 38 (1994) 460-464
67. Coenjaerts F.E., Hoepelman A.I., Scharringa J., Aarts M., Ellerbroek P.M., Bevaart L., Van Strijp J.A., and Janbon G. The Skn7 response regulator of Cryptococcus neoformans is involved in oxidative stress signalling and augments intracellular survival in endothelium. FEMS Yeast Res. 6 (2006) 652-661
68. Cogliati M., Esposto M.C., Clarke D.L., Wickes B.L., and Viviani M.A. Origin of Cryptococcus neoformans var. neoformans diploid strains. J. Clin. Microbiol. 39 (2001) 3889-3894
69. Cossart P., Pizarro-Cerda J., and Lecuit M. Invasion of mammalian cells by Listeria monocytogenes: Functional mimicry to subvert cellular functions. Trends Cell. Biol. 13 (2003) 23-31
70. Cox G.M., Harrison T.S., McDade H.C., Taborda C.P., Heinrich G., Casadevall A., and Perfect J.R. Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect. Immun. 71 (2003) 173-180
71. Cox G.M., McDade H.C., Chen S.C.A., Tucker S.C., Gottfredsson M., Wright L.C., Sorrell T.C., Leidich S.D., Casadevall A., and Ghannoum M.A. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol. Microbiol. 39 (2001) 166-175
72. Cox G.M., Mukherjee J., Cole G.T., Casadevall A., and Perfect J.R. Urease as a virulence factor in experimental cryptococcosis. Infect. Immun. 68 (2000) 443-448
73. Cruz M.C., Fox D.S., and Heitman J. Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans. EMBO J. 20 (2001) 1020-1032
74. Currie B.P., Freundlich L.F., and Casadevall A. Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J. Clin. Microbiol. 32 (1994) 1188-1192
75. D'Souza C.A., Alspaugh J.A., Yue C., Harashima T., Cox G.M., Perfect J.R., and Heitman J. Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol. Cell. Biol. 21 (2001) 3179-3191
76. D'Souza C.A., and Heitman J. It infects me, it infects me not: Phenotypic switching in the fungal pathogen Cryptococcus neoformans. J. Clin. Invest. 108 (2001) 1577-1578
77. da Silva E.G., de Abaroni F., Viani F.C., da Sruiz L., Gandra R.F., Auler M.E., Dias A.L.T., Gambale W., and Paula C.R. Virulence profile of strains of Cryptococcus neoformans var. grubii evaluated by experimental infection in BALB/c mice and correlation with exoenzyme activity. J. Med. Microbiol. 55 (2006) 139-142
78. Dadachova E., Bryan R.A., Frenkel A., Zhang T., Apostolidis C., Nosanchuk J.S., Nosanchuk J.D., and Casadevall A. Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob. Agents Chemother. 48 (2004) 1004-1006
79. Dallasta L.M., Pisarov L.A., Esplen J.E., Werley J.V., Moses A.V., Nelson J.A., and Achim C.L. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155 (1999) 1915-1927
80. Dan J.M., Wang J.P., Lee C.K., and Levitz S.M. Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLoS ONE 3 (2008) e2046
81. Decken K., Kohler G., Palmer-Lehmann K., Wunderlin A., Mattner F., Magram J., Gately M.K., and Alber G. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66 (1998) 4994-5000
82. Del Poeta M. Role of phagocytosis in the virulence of Cryptococcus neoformans. Eukaryotic Cell 3 (2004) 1067-1075
83. Denning D.W., Armstrong R.W., Lewis B.H., and Stevens D.A. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am. J. Med. 91 (1991) 267-272
84. Diamond R.D., and Bennett J.E. Growth of Cryptococcus neoformans within human macrophages in vitro. Infect. Immun. 7 (1973) 231-236
85. Dong Z.M., and Murphy J.W. Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect. Immun. 63 (1995) 2632-2644
86. Dong Z.M., and Murphy J.W. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect. Immun. 65 (1997) 557-563
87. Dramsi S., Levi S., Triller A., and Cossart P. Entry of Listeria monocytogenes into neurons occurs by cell-to-cell spread: An in vitro study. Infect. Immun. 66 (1998) 4461-4468
88. Drevets D.A., and Leenen P.J. Leukocyte-facilitated entry of intracellular pathogens into the central nervous system. Microbes Infect. 2 (2000) 1609-1618
89. Dromer F., Charreire J., Contrepois A., Carbon C., and Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55 (1987) 749-752
90. Dromer F., Mathoulin-Pelissier S., Launay O., and Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: The CryptoA/D study. PLoS Med. 4 (2007) e21
91. Dromer F., Mathoulin S., Dupont B., and Laporte A. Epidemiology of cryptococcosis in France: A 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin. Infect. Dis. 23 (1996) 82-90
92. Dromer F., Ronin O., and Dupont B. Isolation of Cryptococcus neoformans var. gattii from an Asian patient in France: Evidence for dormant infection in healthy subjects. J. Med. Vet. Mycol. 30 (1992) 395-397
93. Edman J.C., and Kwon-Chung K.J. Isolation of the URA5 gene from Cryptococcus neoformans var. neoformans and its use as a selective marker for transformation. Mol. Cell Biol. 10 (1990) 4538-4544
94. Edwards L., Williams A.E., Krieg A.M., Rae A.J., Snelgrove R.J., and Hussell T. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur. J. Immunol. 35 (2005) 273-281
95. Ellerbroek P.M., Walenkamp A.M., Hoepelman A.I., and Coenjaerts F.E. Effects of the capsular polysaccharides of Cryptococcus neoformans on phagocyte migration and inflammatory mediators. Curr. Med. Chem. 11 (2004) 253-266
96. Ellis D., and Pfeiffer T. The ecology of Cryptococcus neoformans. Eur. J. Epidemiol. 8 (1992) 321-325
97. Ellis D.H., and Pfeiffer T.J. Natural habitat of Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 28 (1990) 1642-1644
98. Emery H.S., Shelburne C.P., Bowman J.P., Fallon P.G., Schulz C.A., and Jacobson E.S. Genetic study of oxygen resistance and melanization in Cryptococcus neoformans. Infect. Immun. 62 (1994) 5694-5697
99. Erickson T., Liu L., Gueyikian A., Zhu X., Gibbons J., and Williamson P.R. Multiple virulence factors of Cryptococcus neoformans are dependent on VPH1. Mol. Microbiol. 42 (2001) 1121-1131
100. Erlander S.R. The solution to the seven mysteries of AIDS: The 'Trojan horse'. Med. Hypotheses 44 (1995) 1-9
101. Ernst W.A., Thoma-Uszynski S., Teitelbaum R., Ko C., Hanson D.A., Clayberger C., Krensky A.M., Leippe M., Bloom B.R., Ganz T., and Modlin R.L. Granulysin, a T cell product, kills bacteria by altering membrane permeability. J. Immunol. 165 (2000) 7102-7108
102. Fan M., Currie B.P., Gutell R.R., Ragan M.A., and Casadevall A. The 16S-like, 5.8S and 23S-like rRNAs of the two varieties of Cryptococcus neoformans: Sequence, secondary structure, phylogenetic analysis and restriction fragment polymorphisms. J. Med. Vet. Mycol. 32 (1994) 163-180
103. Feldmesser M., Kress Y., and Casadevall A. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J. Infect. Dis. 177 (1998) 1639-1646
104. Feldmesser M., Kress Y., and Casadevall A. Intracellular crystal formation as a mechanism of cytotoxicity in murine pulmonary Cryptococcus neoformans infection. Infect. Immun. 69 (2001) 2723-2727
105. Feldmesser M., Kress Y., Novikoff P., and Casadevall A. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68 (2000) 4225-4237
106. Fortes S.T., Lazera M.S., Nishikawa M.M., Macedo R.C., and Wanke B. First isolation of Cryptococcus neoformans var. gattii from a native jungle tree in the Brazilian Amazon rainforest. Mycoses 44 (2001) 137-140
107. Fox D.S., Cruz M.C., Sia R.A., Ke H., Cox G.M., Cardenas M.E., and Heitman J. Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans. Mol. Microbiol. 39 (2001) 835-849
108. Franzot S.P., Salkin I.F., and Casadevall A. Cryptococcus neoformans var. grubii: Separate varietal status for Cryptococcus neoformans serotype A isolates. J. Clin. Microbiol. 37 (1999) 838-840
109. Fraser J.A., Giles S.S., Wenink E.C., Geunes-Boyer S.G., Wright J.R., Diezmann S., Allen A., Stajich J.E., Dietrich F.S., Perfect J.R., and Heitman J. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437 (2005) 1360-1364
110. Fraser J.A., and Heitman J. Evolution of fungal sex chromosomes. Mol. Microbiol. 51 (2004) 299-306
111. Fraser J.A., Subaran R.L., Nichols C.B., and Heitman J. Recapitulation of the sexual cycle of the primary fungal pathogen Cryptococcus neoformans var. gattii: Implications for an outbreak on Vancouver Island, Canada. Eukaryotic Cell 2 (2003) 1036-1045
112. Fries B.C., and Casadevall A. Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J. Infect. Dis. 178 (1998) 1761-1766
113. Fries B.C., Lee S.C., Kennan R., Zhao W., Casadevall A., and Goldman D.L. Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis. Infect. Immun. 73 (2005) 1779-1787
114. Fries B.C., Taborda C.P., Serfass E., and Casadevall A. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J. Clin. Invest. 108 (2001) 1639-1648
115. Ganendren R., Carter E., Sorrell T., Widmer F., and Wright L. Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. Microbes Infect. 8 (2006) 1006-1015
116. Garcia-Hermoso D., Janbon G., and Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37 (1999) 3204-3209
117. Garcia-Rivera J., Chang Y.C., Kwon-Chung K.J., and Casadevall A. Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryotic Cell 3 (2004) 385-392
118. Ghannoum M.A. Potential role of phospholipases in virulence and fungal pathogenesis. Clin. Microbiol. Rev. 13 (2000) 122-143
119. Giles S.S., Perfect J.R., and Cox G.M. Cytochrome c peroxidase contributes to the antioxidant defense of Cryptococcus neoformans. Fungal Genet. Biol. 42 (2005) 20-29
120. Goldman D.L., Casadevall A., Cho Y., and Lee S.C. Cryptococcus neoformans meningitis in the rat. Lab. Invest. 75 (1996) 759-770
121. Goldman D., Lee S.C., and Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62 (1994) 4755-4761
122. Goldman D.L., Lee S.C., Mednick A.J., Montella L., and Casadevall A. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect. Immun. 68 (2000) 832-838
123. Gordon M.A., and Vedder D.K. Serologic tests in diagnosis and prognosis of cryptococcosis. JAMA 197 (1966) 961-967
124. Gorlach J., Fox D.S., Cutler N.S., Cox G.M., Perfect J.R., and Heitman J. Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J. 19 (2000) 3618-3629
125. Grab D.J., Nikolskaia O., Kim Y.V., Lonsdale-Eccles J.D., Ito S., Hara T., Fukuma T., Nyarko E., Kim K.J., Stins M.F., Delannoy M.J., Rodgers J., et al. African trypanosome interactions with an in vitro model of the human blood-brain barrier. J. Parasitol. 90 (2004) 970-979
126. Gray J.V., Ogas J.P., Kamada Y., Stone M., Levin D.E., and Herskowitz I. A role for the Pkc1 MAP kinase pathway of Saccharomyces cerevisiae in bud emergence and identification of a putative upstream regulator. EMBO J. 16 (1997) 4924-4937
127. Graybill J.R., Sobel J., Saag M., van Der Horst C., Powderly W., Cloud G., Riser L., Hamill R., and Dismukes W. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. 30 (2000) 47-54
128. Guerrero A., Jain N., Goldman D.L., and Fries B.C. Phenotypic switching in Cryptococcus neoformans. Microbiology 152 (2006) 3-9
129. Hendry A.T., and Bakerspigel A. Factors affecting serum inhibited growth of Candida albicans and Cryptococcus neoformans. Sabouraudia 7 (1969) 219-229
130. Hicks J.K., D Souza C.A., Cox G.M., and Heitman J. Cyclic AMP-dependent protein kinase catalytic subunits have divergent roles in virulence factor production in two varieties of the fungal pathogen Cryptococcus neoformans. Eukaryotic Cell 3 (2004) 14-26
131. Hidore M.R., Nabavi N., Sonleitner F., and Murphy J.W. Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect. Immun. 59 (1991) 1747-1754
132. Hill J.O. CD4+ T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. Med. 175 (1992) 1685-1695
133. Hill J.O., and Harmsen A.G. Intrapulmonary growth and dissemination of an avirulent strain of Cryptococcus neoformans in mice depleted of CD4+ or CD8+ T cells. J. Exp. Med. 173 (1991) 755-758
134. Hoag K.A., Street N.E., Huffnagle G.B., and Lipscomb M.F. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am. J. Respir. Cell. Mol. Biol. 13 (1995) 487-495
135. Hohmann S. Osmotic stress signaling and osmoadaptation in yeasts. Microbiol. Mol. Biol. Rev. 66 (2002) 300-372
136. Hu G., Liu I., Sham A., Stajich J.E., Dietrich F.S., and Kronstad J.W. Comparative hybridization reveals extensive genome variation in the AIDS-associated pathogen Cryptococcus neoformans. Genome Biol. 9 (2008) R41
137. Hu G., Steen B.R., Lian T., Sham A.P., Tam N., Tangen K.L., and Kronstad J.W. Transcriptional regulation by protein kinase A in Cryptococcus neoformans. PLoS Pathog. 3 (2007) e42
138. Huang C., Nong S.H., Mansour M.K., Specht C.A., and Levitz S.M. Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses. Infect. Immun. 70 (2002) 5485-5493
139. Huffnagle G.B. Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection. Biol. Signals 5 (1996) 215-222
140. Huffnagle G.B., Boyd M.B., Street N.E., and Lipscomb M.F. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160 (1998) 2393-2400
141. Huffnagle G.B., Chen G.H., Curtis J.L., McDonald R.A., Strieter R.M., and Toews G.B. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J. Immunol. 155 (1995) 3507-3516
142. Huffnagle G.B., Yates J.L., and Lipscomb M.F. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173 (1991) 793-800
143. Hull C.M., and Heitman J. Genetics of Cryptococcus neoformans. Annu. Rev. Genet. 36 (2002) 557-615
144. Jong A.Y., Stins M.F., Huang S.H., Chen S.H., and Kim K.S. Traversal of Candida albicans across human blood-brain barrier in vitro. Infect. Immun. 69 (2001) 4536-4544
145. Ibrahim A.S., Filler S.G., Alcouloumre M.S., Kozel T.R., Edwards Jr. J.E., and Ghannoum M.A. Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: Role of the capsule. Infect. Immun. 63 (1995) 4368-4374
146. Idnurm A., Bahn Y.S., Nielsen K., Lin X., Fraser J.A., and Heitman J. Deciphering the model pathogenic fungus Cryptococcus neoformans. Nat. Rev. Microbiol. 3 (2005) 753-764
147. Igel H.J., and Bolande R.P. Humoral defense mechanisms in cryptococcosis: Substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J. Infect. Dis. 116 (1966) 75-83
148. Ikeda R., Sugita T., Jacobson E.S., and Shinoda T. Laccase and melanization in clinically important Cryptococcus species other than Cryptococcus neoformans. J. Clin. Microbiol. 40 (2002) 1214-1218
149. Ikeda R., Sugita T., and Shinoda T. Serological relationships of Cryptococcus spp.: Distribution of antigenic factors in Cryptococcus and intraspecies diversity. J. Clin. Microbiol. 38 (2000) 4021-4025
150. Imwidthaya P., and Poungvarin N. Cryptococcosis in AIDS. Postgrad. Med. J. 76 (2000) 85-88
151. Jain N., Li L., McFadden D.C., Banarjee U., Wang X., Cook E., and Fries B.C. Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system. Infect. Immun. 74 (2006) 896-903
152. Janbon G., Himmelreich U., Moyrand F., Improvisi L., and Dromer F. Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol. Microbiol. 42 (2001) 453-467
153. Jarvis J.N., and Harrison T.S. HIV-associated cryptococcal meningitis. AIDS 21 (2007) 2119-2129
154. Jong A.Y., Wu C.H., Jiang S., Feng L., Chen H.M., and Huang S.H. HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to HBMEC. Biochem. Biophys. Res. Commun. 356 (2007) 899-905
155. Kamada Y., Qadota H., Python C.P., Anraku Y., Ohya Y., and Levin D.E. Activation of yeast protein kinase C by Rho1 GTPase. J. Biol. Chem. 271 (1996) 9193-9196
156. Karos M., Chang Y.C., McClelland C.M., Clarke D.L., Fu J., Wickes B.L., and Kwon-Chung K.J. Mapping of the Cryptococcus neoformans MATalpha locus: Presence of mating type-specific mitogen-activated protein kinase cascade homologs. J. Bacteriol. 182 (2000) 6222-6227
157. Kavanaugh L.A., Fraser J.A., and Dietrich F.S. Recent evolution of the human pathogen Cryptococcus neoformans by intervarietal transfer of a 14-gene fragment. Mol. Biol. Evol. 23 (2006) 1879-1890
158. Kawakami K. Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans. Jpn. J. Infect. Dis. 57 (2004) 137-145
159. Kawakami K., Kinjo Y., Yara S., Yara S., Kinjo Y., Uezu K., and Saito A. Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69 (2001) 213-220
160. Kawakami K., Koguchi Y., Qureshi M.H., Yara S., Kinjo Y., Uezu K., and Saito A. NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18. Microbiol. Immunol. 44 (2000) 1043-1050
161. Kawakami K., Kohno S., Kadota J., Tohyama M., Teruya K., Kudeken N., Saito A., and Hara K. T cell-dependent activation of macrophages and enhancement of their phagocytic activity in the lungs of mice inoculated with heat-killed Cryptococcus neoformans: Involvement of IFN-gamma and its protective effect against cryptococcal infection. Microbiol. Immunol. 39 (1995) 135-143
162. Kawakami K., Tohyama M., Teruya K., Kudeken N., Xie Q., and Saito A. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 13 (1996) 123-130
163. Kelly R.M., Chen J., Yauch L.E., and Levitz S.M. Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect. Immun. 73 (2005) 592-598
164. Khawcharoenporn T., Apisarnthanarak A., and Mundy L.M. Non-neoformans cryptococcal infections: A systematic review. Infection 35 (2007) 51-58
165. Kidd S.E., Guo H., Bartlett K.H., Xu J., and Kronstad J.W. Comparative gene genealogies indicate that two clonal lineages of Cryptococcus gattii in British Columbia resemble strains from other geographical areas. Eukaryotic Cell 4 (2005) 1629-1638
166. Kidd S.E., Hagen F., Tscharke R.L., Huynh M., Bartlett K.H., Fyfe M., Macdougall L., Boekhout T., Kwon-Chung K.J., and Meyer W. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. USA 101 (2004) 17258-17263
167. Kiertiburanakul S., Wirojtananugoon S., Pracharktam R., and Sungkanuparph S. Cryptococcosis in human immunodeficiency virus-negative patients. Int. J. Infect. Dis. 10 (2006) 72-78
168. Kinjo T., Miyagi K., Nakamura K., Higa F., Gang X., Miyazato A., Kaku M., Fujita J., and Kawakami K. Adjuvant effect of CpG-oligodeoxynucleotide in anti-fungal chemotherapy against fatal infection with Cryptococcus neoformans in mice. Microbiol. Immunol. 51 (2007) 741-746
169. Kobayashi M., Ito M., Sano K., and Koyama M. Granulomatous and cytokine responses to pulmonary Cryptococcus neoformans in two strains of rats. Mycopathologia 151 (2001) 121-130
170. Koguchi Y., and Kawakami K. Cryptococcal infection and Th1-Th2 cytokine balance. Int. Rev. Immunol. 21 (2002) 423-438
171. Kojima K., Bahn Y.S., and Heitman J. Calcineurin, Mpk1 and Hog1 MAPK pathways independently control fludioxonil antifungal sensitivity in Cryptococcus neoformans. Microbiology 152 (2006) 591-604
172. Kordossis T., Avlami A., Velegraki A., Stefanou I., Georgakopoulos G., Papalambrou C., and Legakis N.J. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med. Mycol. 36 (1998) 335-339
173. Kozel T.R., and Gotschlich E.C. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129 (1982) 1675-1680
174. Kozel T.R., Highison B., and Stratton C.J. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect. Immun. 43 (1984) 574-579
175. Kozel T.R., and Mastroianni R.P. Inhibition of phagocytosis by cryptococcal polysaccharide: Dissociation of the attachment and ingestion phases of phagocytosis. Infect. Immun. 14 (1976) 62-67
176. Krajden S., Summerbell R.C., Kane J., Salkin I.F., Kemna M.E., Rinaldi M.G., Fuksa M., Spratt E., Rodrigues C., and Choe J. Normally saprobic-cryptococci isolated from Cryptococcus neoformans infections. J. Clin. Microbiol. 29 (1991) 1883-1887
177. Kraus P.R., Boily M.J., Giles S.S., Stajich J.E., Allen A., Cox G.M., Dietrich F.S., Perfect J.R., and Heitman J. Identification of Cryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray. Eukaryotic Cell 3 (2004) 1249-1260
178. Kraus P.R., Fox D.S., Cox G.M., and Heitman J. The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin function. Mol. Microbiol. 48 (2003) 1377-1387
179. Kraus P.R., Nichols C.B., and Heitman J. Calcium- and calcineurin-independent roles for calmodulin in Cryptococcus neoformans morphogenesis and high-temperature growth. Eukaryotic Cell 4 (2005) 1079-1087
180. Krockenberger M.B., Canfield P.J., and Malik R. Cryptococcus neoformans in the koala (Phascolarctos cinereus): Colonization by Cn. var. gattii and investigation of environmental sources. Med. Mycol. 40 (2002) 263-272
181. Kunova A., and Krcmery V. Fungaemia due to thermophilic cryptococci: 3 cases of Cryptococcus laurentii bloodstream infections in cancer patients receiving antifungals. Scand. J. Infect. Dis. 31 (1999) 328 328
182. Kwon-Chung K.J. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia 67 (1975) 1197-1200
183. Kwon-Chung K.J. Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia 68 (1976) 821-833
184. Kwon-Chung K.J., and Bennett J.E. Distribution of alpha and alpha mating types of Cryptococcus neoformans among natural and clinical isolates. Am. J. Epidemiol. 108 (1978) 337-340
185. Kwon-Chung K.J., and Bennett J.E. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am. J. Epidemiol. 120 (1984) 123-130
186. Kwon-Chung K.J., Boekhout T., Fell J.W., and Diaz M. (1557) Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 51 (2002) 804-806
187. Kwon-Chung K.J., Bennett J.E., and Rhodes J.C. Taxonomic studies on Filobasidiella species and their anamorphs. Antonie Van Leeuwenhoek 48 (1982) 25-38
188. Kwon-Chung K.J., Edman J.C., and Wickes B.L. Genetic association of mating types and virulence in Cryptococcus neoformans. Infect. Immun. 60 (1992) 602-605
189. Larsen R.A., Pappas P.G., Perfect J., Aberg J.A., Casadevall A., Cloud G.A., James R., Filler S., and Dismukes W.E. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49 (2005) 952-958
190. Lazera M.S., Salmito Cavalcanti M.A., Londero A.T., Trilles L., Nishikawa M.M., and Wanke B. Possible primary ecological niche of Cryptococcus neoformans. Med. Mycol. 38 (2000) 379-383
191. Lee S.C., Dickson D.W., and Casadevall A. Pathology of cryptococcal meningoencephalitis: Analysis of 27 patients with pathogenetic implications. Hum. Pathol. 27 (1996) 839-847
192. Lee K.S., Irie K., Gotoh Y., Watanabe Y., Araki H., Nishida E., Matsumoto K., and Levin D.E. A yeast mitogen-activated protein kinase homolog (Mpk1p) mediates signalling by protein kinase C. Mol. Cell. Biol. 13 (1993) 3067-3075
193. Lendvai N., Qu X.W., Hsueh W., and Casadevall A. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. J. Immunol. 164 (2000) 4367-4374
194. Lengeler K.B., Cox G.M., and Heitman J. Serotype AD strains of Cryptococcus neoformans are diploid or aneuploid and are heterozygous at the mating-type locus. Infect. Immun. 69 (2001) 115-122
195. Lengeler K.B., Davidson R.C., D'Souza C., Harashima T., Shen W.C., Wang P., Pan X., Waugh M., and Heitman J. Signal transduction cascades regulating fungal development and virulence. Microbiol. Mol. Biol. Rev. 64 (2000) 746-785
196. Lengeler K.B., Fox D.S., Fraser J.A., Allen A., Forrester K., Dietrich F.S., and Heitman J. Mating-type locus of Cryptococcus neoformans: A step in the evolution of sex chromosomes. Eukaryotic Cell 1 (2002) 704-718
197. Lester S.J., Kowalewich N.J., Bartlett K.H., Krockenberger M.B., Fairfax T.M., and Malik R. Clinicopathologic features of an unusual outbreak of cryptococcosis in dogs, cats, ferrets, and a bird: 38 cases (January to July 2003). J. Am. Vet. Med. Assoc. 225 (2004) 1716-1722
198. Levitz S.M. Macrophage-Cryptococcus interactions. Immunol. Ser. 60 (1994) 533-543
199. Levitz S.M. Does amoeboid reasoning explain the evolution and maintenance of virulence factors in Cryptococcus neoformans?. Proc. Natl. Acad. Sci. USA 98 (2001) 14760-14762
200. Levitz S.M., and Boekhout T. Cryptococcus: The once-sleeping giant is fully awake. FEMS Yeast Res. 6 (2006) 461-462
201. Levitz S.M., and Dupont M.P. Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro. J. Clin. Invest. 91 (1993) 1490-1498
202. Levitz S.M., Dupont M.P., and Smail E.H. Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect. Immun. 62 (1994) 194-202
203. Levitz S.M., Nong S., Mansour M.K., Huang C., and Specht C.A. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc. Natl. Acad. Sci. USA 98 (2001) 10422-10427
204. Levitz S.M., Nong S.H., Seetoo K.F., Harrison T.S., Speizer R.A., and Simons E.R. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect. Immun. 67 (1999) 885-890
205. Levitz S.M., and Specht C.A. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res. 6 (2006) 513-524
206. Liebmann B., Gattung S., Jahn B., and Brakhage A.A. cAMP signaling in Aspergillus fumigatus is involved in the regulation of the virulence gene pksP and in defense against killing by macrophages. Mol. Genet. Genomics 269 (2003) 420-435
207. Lim T.S., and Murphy J.W. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect. Immun. 30 (1980) 5-11
208. Lin X., and Heitman J. The biology of the Cryptococcus neoformans species complex. Annu. Rev. Microbiol. 60 (2006) 69-105
209. Lin X., Hull C.M., and Heitman J. Sexual reproduction between partners of the same mating type in Cryptococcus neoformans. Nature 434 (2005) 1017-1021
210. Lin X., Litvintseva A.P., Nielsen K., Patel S., Floyd A., Mitchell T.G., and Heitman J. alpha AD alpha hybrids of Cryptococcus neoformans: Evidence of same-sex mating in nature and hybrid fitness. PLoS Genet. 3 (2007) 1975-1990
211. Lin X., Nielsen K., Patel S., and Heitman J. Impact of mating type, serotype, and ploidy on virulence of Cryptococcus neoformans. Infect. Immun. 76 (2008) 2923-2938
212. Lindell D.M., Moore T.A., McDonald R.A., Toews G.B., and Huffnagle G.B. Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J. Immunol. 174 (2005) 7920-7928
213. Litvintseva A.P., Kestenbaum L., Vilgalys R., and Mitchell T.G. Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J. Clin. Microbiol. 43 (2005) 556-564
214. Litvintseva A.P., Kestenbaum L., Vilgalys R., and Mitchell T.G. Prevalence of clinical isolates of Cryptococcus gatti serotype C among patients with AIDS in Sub-Saharan Africa. J. Infect. Dis. 192 (2005) 888-892
215. Litvintseva A.P., Lin X., Templeton I., Heitman J., and Mitchell T.G. Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa. PLoS Pathog. 3 (2007) e114
216. Litvintseva A.P., Thakur R., Reller L.B., and Mitchell T.G. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J. Infect. Dis. 192 (2005) 888-892
217. Litvintseva A.P., Thakur R., Vilgalys R., and Mitchell T.G. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics 172 (2006) 2223-2238
218. Liu X., Hu G., Panepinto J., and Williamson P.R. Role of a VPS41 homologue in starvation response, intracellular survival and virulence of Cryptococcus neoformans. Mol. Microbiol. 61 (2006) 1132-1146
219. Loftus B.J., Fung E., Roncaglia P., Rowley D., Amedeo P., Bruno D., Vamathevan J., Miranda M., Anderson I.J., Fraser J.A., Allen J.E., Bosdet I.E., et al. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307 (2005) 1321-1324
220. Loison J., Bouchara J.P., Gueho E., deGentile L., Cimon B., Chennebault J.M., and Chabasse D. First report of Cryptococcus albidus septicaemia in an HIV patient. J. Infect. 33 (1996) 139-140
221. Lortholary O., Improvisi L., Fitting C., Cavaillon J.M., and Dromer F. Influence of gender and age on course of infection and cytokine responses in mice with disseminated Cryptococcus neoformans infection. Clin. Microbiol. Infect. 8 (2002) 31-37
222. Lortholary O., Improvisi L., Nicolas M., Provost F., Dupont B., and Dromer F. Fungemia during murine cryptococcosis sheds some light on pathophysiology. Med. Mycol. 37 (1999) 169-174
223. Luberto C., Martinez-Marino B., Taraskiewicz D., Bolanos B., Chitano P., Toffaletti D.L., Cox G.M., Perfect J.R., Hannun Y.A., Balish E., and Del Poeta M. Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J. Clin. Invest. 112 (2003) 1080-1094
224. Lupo P., Chang Y.C., Kelsall B.L., Farber J.M., Pietrella D., Vecchiarelli A., Leon F., and Kwon-Chung K.J. The presence of capsule in Cryptococcus neoformans influences the gene expression profile in dendritic cells during interaction with the fungus. Infect. Immun. 76 (2008) 1581-1589
225. Lutz J.E., Clemons K.V., and Stevens D.A. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J. Antimicrob. Chemother. 46 (2000) 437-442
226. Ma H., Croudace J.E., Lammas D.A., and May R.C. Expulsion of live pathogenic yeast by macrophages. Curr. Biol. 16 (2006) 2156-2160
227. Ma H., Croudace J.E., Lammas D.A., and May R.C. Direct cell-to-cell spread of a pathogenic yeast. BMC Immunol. 8 (2007) 15
228. Ma L.L., Spurrell J.C., Wang J.F., Neely G.G., Epelman S., Krensky A.M., and Mody C.H. CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15. J. Immunol. 169 (2002) 5787-5795
229. Ma L.L., Wang C.L., Neely G.G., Epelman S., Krensky A.M., and Mody C.H. NK cells use perforin rather than granulysin for anticryptococcal activity. J. Immunol. 173 (2004) 3357-3365
230. MacDougall L., Kidd S.E., Galanis E., Mak S., Leslie M.J., Cieslak P.R., Kronstad J.W., Morshed M.G., and Bartlett K.H. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg. Infect. Dis. 13 (2007) 42-50
231. Malliaris S.D., Steenbergen J.N., and Casadevall A. Cryptococcus neoformans var. gattii can exploit Acanthamoeba castellanii for growth. Med. Mycol. 42 (2004) 149-158
232. Mambula S.S., Simons E.R., Hastey R., Selsted M.E., and Levitz S.M. Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans. Infect. Immun. 68 (2000) 6257-6264
233. Mansour M.K., Latz E., and Levitz S.M. Cryptococcus neoformans glycoantigens are captured by multiple lectin receptors and presented by dendritic cells. J. Immunol. 176 (2006) 3053-3061
234. Mansour M.K., Yauch L.E., Rottman J.B., and Levitz S.M. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect. Immun. 72 (2004) 1746-1754
235. Martinez L.R., Garcia-Rivera J., and Casadevall A. Cryptococcus neoformans var. neoformans (serotype D) strains are more susceptible to heat than C. neoformans var. grubii (serotype A) strains. J. Clin. Microbiol. 39 (2001) 3365-3367
236. Mayanja-Kizza H., Oishi K., Mitarai S., Yamashita H., Nalongo K., Watanabe K., Izumi T., Ococi J., Augustine K., Mugerwa R., Nagatake T., and Matsumoto K. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. 26 (1998) 1362-1366
237. McClelland C.M., Chang Y.C., and Kwon-Chung K.J. High frequency transformation of Cryptococcus neoformans and Cryptococcus gattii by Agrobacterium tumefaciens. Fungal Genet. Biol. 42 (2005) 904-913
238. McCurdy L.H., and Morrow J.D. Infections due to non-neoformans cryptococcal species. Compr. Ther. 29 (2003) 95-101
239. McFadden D.C., De Jesus M., and Casadevall A. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J. Biol. Chem. 281 (2006) 1868-1875
240. Mednick A.J., Feldmesser M., Rivera J., and Casadevall A. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur. J. Immunol. 33 (2003) 1744-1753
241. Meyer W., Castaneda A., Jackson S., Huynh M., and Castaneda E. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg. Infect. Dis. 9 (2003) 189-195
242. Meyer W., Kaocharoen S., Trilles L., Jover-Botella A., Escandón P., Castañeda E., Tsui C., Hagen F., and Boekhout T. Global molecular epidemiology of Cryptococcus gattii VGII isolates traces the origin of the Vancouver Island outbreak to Latin American. 24th Fungal Genetics Conference (2007)
243. Meyer W., Marszewska K., Amirmostofian M., Igreja R.P., Hardtke C., Methling K., Viviani M.A., Chindamporn A., Sukroongreung S., John M.A., Ellis D.H., and Sorrell T.C. Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis 20 (1999) 1790-1799
244. Miller M.F., and Mitchell T.G. Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect. Immun. 59 (1991) 24-28
245. Missall T.A., Lodge J.K., and McEwen J.E. Mechanisms of resistance to oxidative and nitrosative stress: Implications for fungal survival in mammalian hosts. Eukaryotic Cell 3 (2004) 835-846
246. Missall T.A., Moran J.M., Corbett J.A., and Lodge J.K. Distinct stress responses of two functional laccases in Cryptococcus neoformans are revealed in the absence of the thiol-specific antioxidant Tsa1. Eukaryotic Cell 4 (2005) 202-208
247. Mitchell T.G., and Friedman L. In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans. Infect. Immun. 5 (1972) 491-498
248. Mitchell T.G., and Perfect J.R. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8 (1995) 515-548
249. Miyagi K., Kawakami K., Kinjo Y., Uezu K., Kinjo T., Nakamura K., and Saito A. CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells. Clin. Exp. Immunol. 140 (2005) 220-229
250. Mody C.H., Lipscomb M.F., Street N.E., and Toews G.B. Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J. Immunol. 144 (1990) 1472-1477
251. Mody C.H., Tyler C.L., Sitrin R.G., Jackson C., and Toews G.B. Interferon-gamma activates rat alveolar macrophages for anticryptococcal activity. Am. J. Respir. Cell Mol. Biol. 5 (1991) 19-26
252. Mohanty S.K., Vaiphei K., Dutta U., and Singh K. Granulomatous cryptococcal lymphadenitis in immunocompetent individuals: Report of two cases. Histopathology 42 (2003) 96-97
253. Moyrand F., Chang Y.C., Himmelreich U., Kwon-Chung K.J., and Janbon G. Cas3p belongs to a seven-member family of capsule structure designer proteins. Eukaryotic Cell 3 (2004) 1513-1524
254. Mukherjee J., Scharff M.D., and Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60 (1992) 4534-4541
255. Murphy J.W., Hidore M.R., and Nabavi N. Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformans. Infect. Immun. 59 (1991) 1476-1488
256. Murphy J.W., Hidore M.R., and Wong S.C. Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans. J. Clin. Invest. 91 (1993) 1553-1566
257. Mwaba P., Mwansa J., Chintu C., Pobee J., Scarborough M., Portsmouth S., and Zumla A. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad. Med. J. 77 (2001) 769-773
258. Mylonakis E., Ausubel F.M., Perfect J.R., Heitman J., and Calderwood S.B. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc. Natl. Acad. Sci. USA 99 (2002) 15675-15680
259. Mylonakis E., Moreno R., El Khoury J.B., Idnurm A., Heitman J., Calderwood S.B., Ausubel F.M., and Diener A. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect. Immun. 73 (2005) 3842-3850
260. Nabavi N., and Murphy J.W. In vitro binding of natural killer cells to Cryptococcus neoformans targets. Infect. Immun. 50 (1985) 50-57
261. Nanno M., Shiohara T., Yamamoto H., Kawakami K., and Ishikawa H. gammadelta T cells: Firefighters or fire boosters in the front lines of inflammatory responses. Immunol. Rev. 215 (2007) 103-113
262. Nassar F., Brummer E., and Stevens D.A. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Antimicrob. Agents Chemother. 39 (1995) 2490-2493
263. Nessa K., Gross N.T., Jarstrand C., Johansson A., and Camner P. In vivo interaction between alveolar macrophages and Cryptococcus neoformans. Mycopathologia 139 (1997) 1-7
264. Nessa K., Johansson A., Jarstrand C., and Camner P. Alveolar macrophage reaction to Candida species. Lett. Appl. Microbiol. 25 (1997) 181-185
265. Nguyen L., and Pieters J. The Trojan horse: Survival tactics of pathogenic mycobacteria in macrophages. Trends Cell Biol. 15 (2005) 269-276
266. Nielsen K., Cox G.M., Litvintseva A.P., Mylonakis E., Malliaris S.D., Benjamin Jr. D.K., Giles S.S., Mitchell T.G., Casadevall A., Perfect J.R., and Heitman J. Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect. Immun. 73 (2005) 4922-4933
267. Nielsen K., Cox G.M., Wang P., Toffaletti D.L., Perfect J.R., and Heitman J. Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect. Immun. 71 (2003) 4831-4841
268. Nishikawa M.M., Lazera M.S., Barbosa G.G., Trilles L., Balassiano B.R., Macedo R.C., Bezerra C.C., Perez M.A., Cardarelli P., and Wanke B. Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: Analysis of host and regional patterns. J. Clin. Microbiol. 41 (2003) 73-77
269. Nosanchuk J.D., and Casadevall A. Cellular charge of Cryptococcus neoformans: Contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect. Immun. 65 (1997) 1836-1841
270. Nosanchuk J.D., Rosas A.L., Lee S.C., and Casadevall A. Melanisation of Cryptococcus neoformans in human brain tissue. Lancet 355 (2000) 2049-2050
271. Nosanchuk J.D., Shoham S., Fries B.C., Shapiro D.S., Levitz S.M., and Casadevall A. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann. Intern. Med. 132 (2000) 205-208
272. Odom A., Muir S., Lim E., Toffaletti D.L., Perfect J., and Heitman J. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16 (1997) 2576-2589
273. Olszewski M.A., Noverr M.C., Chen G.H., Toews G.B., Cox G.M., Perfect J.R., and Huffnagle G.B. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am. J. Pathol. 164 (2004) 1761-1771
274. Pappas P.G., Bustamante B., Ticona E., Hamill R.J., Johnson P.C., Reboli A., Aberg J., Hasbun R., and Hsu H.H. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis. 189 (2004) 2185-2191
275. Perfect J.R. Cryptococcosis. Infect. Dis. Clin. North. Am. 3 (1989) 77-102
276. Perfect J.R. Cryptococcus neoformans: A sugar-coated killer with designer genes. FEMS Immunol. Med. Microbiol. 45 (2005) 395-404
277. Perfect J.R. Management of cryptococcosis: How are we doing?. PLoS Med. 4 (2007) e47
278. Petter R., Kang B.S., Boekhout T., Davis B.J., and Kwon-Chung K.J. A survey of heterobasidiomycetous yeasts for the presence of the genes homologous to virulence factors of Filobasidiella neoformans, CNLAC1 and CAP59. Microbiology 147 (2001) 2029-2036
279. Perfect J.R., Lang S.D., and Durack D.T. Chronic cryptococcal meningitis: A new experimental model in rabbits. Am. J. Pathol. 101 (1980) 177-194
280. Pietrella D., Corbucci C., Perito S., Bistoni G., and Vecchiarelli A. Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation. Infect. Immun. 73 (2005) 820-827
281. Pietrella D., Fries B., Lupo P., Bistoni F., Casadevall A., and Vecchiarelli A. Phenotypic switching of Cryptococcus neoformans can influence the outcome of the human immune response. Cell. Microbiol. 5 (2003) 513-522
282. Polacheck I. The discovery of melanin production in Cryptococcus neoformans and its impact on diagnosis and the study of virulence. Zentralbl. Bakteriol. 276 (1991) 120-123
283. Powderly W.G., Saag M.S., Cloud G.A., Robinson P., Meyer R.D., Jacobson J.M., Graybill J.R., Sugar A.M., McAuliffe V.J., Follansbee S.E., et al., NIAID Mycoses Study Group, the AIDS Clinical Trials Group. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N. Engl. J. Med. 326 (1992) 793-798
284. Pukkila-Worley R., and Alspaugh J.A. Cyclic AMP signaling in Cryptococcus neoformans. FEMS Yeast Res. 4 (2004) 361-367
285. Rachini A., Pietrella D., Lupo P., Torosantucci A., Chiani P., Bromuro C., Proietti C., Bistoni F., Cassone A., and Vecchiarelli A. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75 (2007) 5085-5094
286. Rakesh V., Schweitzer A.D., Zaragoza O., Bryan R., Wong K., Datta A., Casadevall A., and Dadachova E. Finite-Element Model of Interaction between Fungal Polysaccharide and Monoclonal Antibody in the Capsule of Cryptococcus neoformans. J. Phys. Chem. B 112 (2008) 8514-8522
287. Retini C., Vecchiarelli A., Monari C., Tascini C., Bistoni F., and Kozel T.R. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64 (1996) 2897-2903
288. Ricardo-Dukelow M., Kadiu I., Rozek W., Schlautman J., Persidsky Y., Ciborowski P., Kanmogne G.D., and Gendelman H.E. HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: New insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J. Neuroimmunol. 185 (2007) 37-46
289. Ring A., Weiser J.N., and Tuomanen E.I. Pneumococcal trafficking across the blood-brain barrier. Molecular analysis of a novel bidirectional pathway. J. Clin. Invest. 102 (1998) 347-360
290. Rivera J., Feldmesser M., Cammer M., and Casadevall A. Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect. Immun. 66 (1998) 5027-5030
291. Rivera J., Mukherjee J., Weiss L.M., and Casadevall A. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: A role for nitric oxide. J. Immunol. 168 (2002) 3419-3427
292. Rocha C.R., Schroppel K., Harcus D., Marcil A., Dignard D., Taylor B.N., Thomas D.Y., Whiteway M., and Leberer E. Signaling through adenylyl cyclase is essential for hyphal growth and virulence in the pathogenic fungus Candida albicans. Mol. Biol. Cell 12 (2001) 3631-3643
293. Rodrigues M.L., Nakayasu E.S., Oliveira D.L., Nimrichter L., Nosanchuk J.D., Almeida I.C., and Casadevall A. Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryotic Cell 7 (2008) 58-67
294. Rosa E.S.L.K., Staats C.C., Goulart L.S., Morello L.G., Pelegrinelli Fungaro M.H., Schrank A., and Vainstein M.H. Identification of novel temperature-regulated genes in the human pathogen Cryptococcus neoformans using representational difference analysis. Res. Microbiol. 159 (2008) 221-229
295. Rosas A.L., and Casadevall A. Melanization affects susceptibility of Cryptococcus neoformans to heat and cold. FEMS Microbiol. Lett. 153 (1997) 265-272
296. Rubin L.L., and Staddon J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 22 (1999) 11-28
297. Ruma P., Chen S.C., Sorrell T.C., and Brownlee A.G. Characterization of Cryptococcus neoformans by random DNA amplification. Lett. Appl. Microbiol. 23 (1996) 312-316
298. Saag M.S., Graybill R.J., Larsen R.A., Pappas P.G., Perfect J.R., Powderly W.G., Sobel J.D., and Dismukes W.E. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30 (2000) 710-718
299. Sanford D.G., and Stollar B.D. Characterization of anti-Z-DNA antibody binding sites on Z-DNA by nuclear magnetic resonance spectroscopy. J. Biol. Chem. 265 (1990) 18608-18614
300. Santangelo R.T., Nouri-Sorkhabi M.H., Sorrell T.C., Cagney M., Chen S.C., Kuchel P.W., and Wright L.C. Biochemical and functional characterisation of secreted phospholipase activities from Cryptococcus neoformans in their naturally occurring state. J. Med. Microbiol. 48 (1999) 731-740
301. Santangelo R., Zoellner H., Sorrell T., Wilson C., Donald C., Djordjevic J., Shounan Y., and Wright L. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect. Immun. 72 (2004) 2229-2239
302. Sau K., Mambula S.S., Latz E., Henneke P., Golenbock D.T., and Levitz S.M. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J. Biol. Chem. 278 (2003) 37561-37568
303. Savoy A.C., Lupan D.M., Manalo P.B., Roberts J.S., Schlageter A.M., Weinhold L.C., and Kozel T.R. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect. Immun. 65 (1997) 1800-1807
304. Seaton R.A., Naraqi S., Wembri J.P., and Warrell D.A. Predictors of outcome in Cryptococcus neoformans var. gattii meningitis. QJM 89 (1996) 423-428
305. Shao X., Mednick A., Alvarez M., van Rooijen N., Casadevall A., and Goldman D.L. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175 (2005) 3244-3251
306. Shea J.M., Kechichian T.B., Luberto C., and Del Poeta M. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect. Immun. 74 (2006) 5977-5988
307. Shibuya K., Hirata A., Omuta J., Sugamata M., Katori S., Saito N., Murata N., Morita A., Takahashi K., Hasegawa C., Mitsuda A., Hatori T., and Nonaka H. Granuloma and cryptococcosis. J. Infect. Chemother. 11 (2005) 115-122
308. Siddiqui A.A., Brouwer A.E., Wuthiekanun V., Jaffar S., Shattock R., Irving D., Sheldon J., Chierakul W., Peacock S., Day N., White N.J., and Harrison T.S. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J. Immunol. 174 (2005) 1746-1750
309. Sirinavin S., Intusoma U., and Tuntirungsee S. Mother-to-child transmission of Cryptococcus neoformans. Pediatr. Infect. Dis. J. 23 (2004) 278-279
310. Snelgrove R.J., Edwards L., Williams A.E., Rae A.J., and Hussell T. In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection. J. Immunol. 177 (2006) 5509-5516
311. Sorrell T.C. Cryptococcus neoformans variety gattii. Med. Mycol. 39 (2001) 155-168
312. Specht C.A., Nong S., Dan J.M., Lee C.K., and Levitz S.M. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J. Infect. Dis. 196 (2007) 796-800
313. Speed B., and Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin. Infect. Dis. 21 (1995) 28-34 discussion 35-26
314. Steen B.R., Lian T., Zuyderduyn S., MacDonald W.K., Marra M., Jones S.J., and Krostand J.W. Temperature-regulated transcription in the pathogenic fungus Cryptococcus neoformans. Genome Res. 12 (2002) 1386-1400
315. Steenbergen J.N., and Casadevall A. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect. 5 (2003) 667-675
316. Steenbergen J.N., Nosanchuk J.D., Malliaris S.D., and Casadevall A. Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect. Immun. 71 (2003) 4862-4872
317. Steenbergen J.N., Shuman H.A., and Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc. Natl. Acad. Sci. USA 98 (2001) 15245-15250
318. Sun S., and Xu J. Genetic analyses of a hybrid cross between serotypes A and D strains of the human pathogenic fungus Cryptococcus neoformans. Genetics 177 (2007) 1475-1486
319. Syme R.M., Spurrell J.C., Amankwah E.K., Green F.H., and Mody C.H. Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes. Infect. Immun. 70 (2002) 5972-5981
320. Szilagyi G., Reiss F., and Smith J.C. The anticryptococcal factor of blood serum. A preliminary report. J. Invest. Dermatol. 46 (1966) 306-308
321. Tang R.J., Breger J., Idnurm A., Gerik K.J., Lodge J.K., Heitman J., Calderwood S.B., and Mylonakis E. Cryptococcus neoformans gene involved in mammalian pathogenesis identified by a Caenorhabditis elegans progeny-based approach. Infect. Immun. 73 (2005) 8219-8225
322. Toborek M., Lee Y.W., Flora G., Pu H., Andras I.E., Wylegala E., Hennig B., and Nath A. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell. Mol. Neurobiol. 25 (2005) 181-199
323. Tohyama M., Kawakami K., Futenma M., and Saito A. Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide. Clin. Exp. Immunol. 103 (1996) 436-441
324. Torres-Guererro H., and Edman J.C. Melanin-deficient mutants of Cryptococcus neoformans. J. Med. Vet. Mycol. 32 (1994) 303-313
325. Torres-Rodriguez J.M., Morera Y., Baro T., Corominas J.M., and Castaneda E. Pathogenicity of Cryptococcus neoformans var. gattii in an immunocompetent mouse model. Med. Mycol. 41 (2003) 59-63
326. Trilles L., Fernandez-Torres B., Lazera Mdos S., Wanke B., and Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42 (2004) 4815-4817
327. Tripathi P., Tripathi P., Kashyap L., and Singh V. The role of nitric oxide in inflammatory reactions. FEMS Immunol. Med. Microbiol. 51 (2007) 443-452
328. Tucker S.C., and Casadevall A. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. USA 99 (2002) 3165-3170
329. Turrens J.F., and Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 191 (1980) 421-427
330. Uezu K., Kawakami K., Miyagi K., Kinjo Y., Kinjo T., Ishikawa H., and Saito A. Accumulation of gammadelta T cells in the lungs and their regulatory roles in Th1 response and host defense against pulmonary infection with Cryptococcus neoformans. J. Immunol. 172 (2004) 7629-7634
331. Uicker W.C., Doyle H.A., McCracken J.P., Langlois M., and Buchanan K.L. Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Med. Mycol. 43 (2005) 27-38
332. Vaishnav V.V., Bacon B.E., O'Neill M., and Cherniak R. Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67. Carbohydr. Res. 306 (1998) 315-330
333. van der Horst C.M., Saag M.S., Cloud G.A., Hamill R.J., Graybill J.R., Sobel J.D., Johnson P.C., Tuazon C.U., Kerkering T., Moskovitz B.L., Powderly W.G., and Dismukes W.E. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337 (1997) 15-21
334. van Duin D., Casadevall A., and Nosanchuk J.D. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob. Agents Chemother. 46 (2002) 3394-3400
335. Vanbreuseghem R., and Takashio M. An atypical strain of Cryptococcus neoformans (San Felice) Vuillemin 1894. II. Cryptococcus neoformans var. gattii var. nov. Ann. Soc. Belges. Med. Trop. Parasitol. Mycol. 50 (1970) 695-702
336. Varma A., and Kwon-Chung K.J. DNA probe for strain typing of Cryptococcus neoformans. J. Clin. Microbiol. 30 (1992) 2960-2967
337. Vartivarian S.E., Anaissie E.J., Cowart R.E., Sprigg H.A., Tingler M.J., and Jacobson E.S. Regulation of cryptococcal capsular polysaccharide by iron. J. Infect. Dis. 167 (1993) 186-190
338. Vecchiarelli A., Pietrella D., Dottorini M., Monari C., Retini C., Todisco T., and Bistoni F. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol. 98 (1994) 217-223
339. Verna J., Lodder A., Lee K., Vagts A., and Ballester R. A family of genes required for maintenance of cell wall integrity and for the stress response in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 94 (1997) 13804-13809
340. Vieira O.V., Botelho R.J., and Grinstein S. Phagosome maturation: Aging gracefully. Biochem. J. 366 (2002) 689-704
341. Villena S.N., Pinheiro R.O., Pinheiro C.S., Nunes M.P., Takiya C.M., Dosreis G.A., Previato J.O., Mendonca-Previato L., and Freire-de-Lima C.G. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell. Microbiol. 10 (2008) 1274-1285
342. Voskoboinik I., Smyth M.J., and Trapani J.A. Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol. 6 (2006) 940-952
343. Walton F.J., Idnurm A., and Heitman J. Novel gene functions required for melanization of the human pathogen Cryptococcus neoformans. Mol. Microbiol. 57 (2005) 1381-1396
344. Wang Y., and Casadevall A. Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl. Environ. Microbiol. 60 (1994) 3864-3866
345. Wang P., Perfect J.R., and Heitman J. The G-protein beta subunit GPB1 is required for mating and haploid fruiting in Cryptococcus neoformans. Mol. Cell. Biol. 20 (2000) 352-362
346. Waugh M.S., Nichols C.B., DeCesare C.M., Cox G.M., Heitman J., and Alspaugh J.A. Ras1 and Ras2 contribute shared and unique roles in physiology and virulence of Cryptococcus neoformans. Microbiology 148 (2002) 191-201
347. Waugh M.S., Vallim M.A., Heitman J., and Alspaugh J.A. Ras1 controls pheromone expression and response during mating in Cryptococcus neoformans. Fungal Genet. Biol. 38 (2003) 110-121
348. Weinberg P.B., Becker S., Granger D.L., and Koren H.S. Growth inhibition of Cryptococcus neoformans by human alveolar macrophages. Am. Rev. Respir. Dis. 136 (1987) 1242-1247
349. Williamson P.R. Laccase and melanin in the pathogenesis of Cryptococcus neoformans. Front. Biosci. 2 (1997) e99-107
350. Wiseman J.C., Ma L.L., Marr K.J., Jones G.J., and Mody C.H. Perforin-dependent cryptococcal microbicidal activity in NK cells requires PI3K-dependent ERK1/2 signaling. J. Immunol. 178 (2007) 6456-6464
351. Wozniak K.L., Vyas J.M., and Levitz S.M. In vivorole of dendritic cells in a murine model of pulmonary cryptococcosis. Infect. Immun. 74 (2006) 3817-3824
352. Xie Q., Kawakami K., Kudeken N., Zhang T., Qureshi M.H., and Saito A. Different susceptibility of three clinically isolated strains of Cryptococcus neoformans to the fungicidal effects of reactive nitrogen and oxygen intermediates: Possible relationships with virulence. Microbiol. Immunol. 41 (1997) 725-731
353. Xu J., Luo G., Vilgalys R.J., Brandt M.E., and Mitchell T.G. Multiple origins of hybrid strains of Cryptococcus neoformans with serotype AD. Microbiology 148 (2002) 203-212
354. Xu J., Vilgalys R., and Mitchell T.G. Multiple gene genealogies reveal recent dispersion and hybridization in the human pathogenic fungus Cryptococcus neoformans. Mol. Ecol. 9 (2000) 1471-1481
355. Xue C., Bahn Y.S., Cox G.M., and Heitman J. G protein-coupled receptor Gpr4 senses amino acids and activates the cAMP-PKA pathway in Cryptococcus neoformans. Mol. Biol. Cell 17 (2006) 667-679
356. Yauch L.E., Lam J.S., and Levitz S.M. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog. 2 (2006) e120
357. Yue C., Cavallo L.M., Alspaugh J.A., Wang P., Cox G.M., Perfect J.R., and Heitman J. The STE12alpha homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. Genetics 153 (1999) 1601-1615
358. Zaragoza O., Alvarez M., Telzak A., Rivera J., and Casadevall A. The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect. Immun. 75 (2007) 2729-2739
359. Zaragoza O., and Casadevall A. Experimental modulation of capsule size in Cryptococcus neoformans. Biol. Proced. Online 6 (2004) 10-15
360. Zaragoza O., Chrisman C.J., Castelli M.V., Frases S., Cuenca-Estrella M., Rodriguez Tudela J.L., and Casadevall A. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell. Microbiol. (2008) (Epub ahead of print)
361. Zhang T., Kawakami K., Qureshi M.H., Okamura H., Kurimoto M., and Saito A. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect. Immun. 65 (1997) 3594-3599
362. Zheng C.F., Jones G.J., Shi M., Wiseman J.C., Marr K.J., Berenger B.M., Huston S.M., Gill M.J., Krensky A.M., Kubes P., and Mody C.H. Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2R{beta} that is defective in HIV-infected patients. J. Immunol. 180 (2008) 7221-7229
363. Zheng C.F., Ma L.L., Jones G.J., Gill M.J., Krensky A.M., Kubes P., and Mody C.H. Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. Blood 109 (2007) 2049-2057
364. Zhou Q., Gault R.A., Kozel T.R., and Murphy W.J. Protection from direct cerebral Cryptococcus infection by interferon-gamma-dependent activation of microglial cells. J. Immunol. 178 (2007) 5753-5761
365. Zhu X., and Williamson P.R. A CLC-type chloride channel gene is required for laccase activity and virulence in Cryptococcus neoformans. Mol. Microbiol. 50 (2003) 1271-1281
366. Zhu X., and Williamson P.R. Role of laccase in the biology and virulence of Cryptococcus neoformans. FEMS Yeast Res. 5 (2004) 1-10